Alignment Healthcare, Inc. (ALHC) fair value analysis
Nasdaq · Updated 2026-10-19
ALHC price how computed
Valuation status
Awaiting full valuationALHC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $8.28
- Sector
- Healthcare
- 12-month range
- $7.54–$24.56
- Market cap
- $1.72B
- From 52-week high
- -66.3%
- Shares outstanding
- 207M
- Rank in Healthcare by quality score
- #198 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Alignment Healthcare, Inc. operates as a managed care company that provides health insurance plans and healthcare services primarily to Medicare Advantage beneficiaries. The company operates across multiple states throughout the United States.
ALHC currently ranks #198 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.72B
- P/E (trailing)
- 24x
- Revenue (TTM)
- $4.58B
- Net margin
- 0.9%
- EPS (TTM)
- $0.34
- Gross margin
- 13.5%
- Debt / equity
- 1.25
- Revenue growth (3-yr avg)
- 64.1%
- Shares outstanding
- 207M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 47 · neutral
- 50-day average
- $10.94
- 200-day average
- $17.45
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+30.8%)
2026-03 ▲ beat (+33.3%)
2025-12 ▲ beat (+66.7%)
2025-09 ▲ beat (+1100.0%)
2025-06 ▲ beat (+1300.0%)
2025-03 ▲ beat (+200.0%)
2024-12 ▲ beat (+32.1%)
2024-09 ▼ miss (-75.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 2 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $13.3
- Target vs last price
- +60.6%
What our data shows for ALHC
- Our model validated 4 trailing price-to-earnings windows for ALHC, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $7.54–$24.56.
- The 14-day relative strength index sits at a neutral 47.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ALHC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ALHC news
TickrTrends' derived news-sentiment signal for ALHC is currently leaning positive, computed from recent coverage.
- Analysts Estimate Alignment Healthcare (ALHC) to Report a Decline in Earnings: What to Look Out for (zacks.com, 2026-10-22)
- Alignment Health Expands Medicare Advantage Plan to Nye County for 2027 (manilatimes.net, 2026-10-21)
- Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors (manilatimes.net, 2026-10-19)
More ALHC news
- ALHC Maintained by UBS -- Price Target Lowered to $9.00 (gurufocus.com, 2026-10-12)
- Alignment Healthcare (ALHC) Shares Rebound 7% After CMS Star Ratings Reveal Mixed Results (gurufocus.com, 2026-10-12)
- Alignment Healthcare bounces back 7% after sharp prior-session drop (ALHC:NASDAQ) (seekingalpha.com, 2026-10-12)
What people are saying
Follow the ALHC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ALHC showed movement this week as the Relative Strength Index transitioned from oversold territory into neutral range, suggesting a shift in near-term momentum dynamics for the Healthcare sector company. The valuation assessment remains awaiting full valuation pending additional analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — # ALHC Weekly Indicator Summary TickrTrends' derived indicators for ALHC showed a shift this week as the Relative Strength Index moved from neutral territory into oversold conditions. The stock's current valuation verdict remains awaiting full valuation, indicating that comprehensive assessment is still pending. This movement into oversold RSI levels may warrant monitoring as the stock continues to be evaluated.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ALHC stock undervalued?
ALHC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ALHC's TickrTrends verdict?
ALHC is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does ALHC compare to other Healthcare stocks?
ALHC ranks #198 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ALHC overbought or oversold?
ALHC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ALHC report earnings next?
ALHC's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does ALHC usually beat earnings estimates?
Over its last 8 reported quarters ALHC beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALHC?
Of 14 analysts covering ALHC, 12 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $13.3 (+60.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.